4
Changes in Ownership
Vir Biotechnology, Inc. Filed Acc 0001628280-26-011329
EVP and Chief Medical Officer sold 2,089 shares at $7.45 ($15,569)
- EVP and Chief Medical Officer acquired 55,000 shares (grant or award)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Eisner Mark EVP and Chief Medical Officer | 2026-02-22 | Grant or award 10b5-1 | +55,000 | 159,618 | D | ||
| Eisner Mark EVP and Chief Medical Officer | 2026-02-23 | Sale 10b5-1 | −2,089 | $7.45 | $15,569 | 157,529 | D |
| Derivatives | |||||||
| Eisner Mark EVP and Chief Medical Officer | 2026-02-22 | Grant or award · Stock Option (Right to Buy) 10b5-1 | +110,000 | 110,000 | D | ||
| Open-market sales · 2,089 sh · avg $7.45 · $15,569 | |||||||
Loading xslF345X05/wk-form4_1771978287.xml…